Therapy with high-dose intravenous immunoglobulin (IVIG) has been demonstrated to be useful in several diseases, from autoimmunity mediated by autoantibodies (such as Guillain-Barré syndrome, myasthenia gravis, etc) to primary and secondary antibody deficiency states. It has also been recommended in inflammatory conditions (myopathies) and in some infectious diseases (viral pneumonitis after transplantation, severe or recurrent Clostridium difficile colitis) (UK Guidelines, 2009). This kind of treatment is sometimes offered to ME/CFS patients too, with a wide range of doses, frequency and number of administrations. In what follows I have searched for trials of IVIG in ME/CFS patients, seeking for evidences of efficacy.
I collected a total of 5 studies on the use of IVIG in ME/CFS patients. One of them (Rowe KS 1997) has been discarded because it is on pediatric population. Another one (Tirelli U et al. 2013) represents a retrospective…
View original post 497 altre parole